| fadrozole vs megestrol acetate | No demonstrated result vomiting by 122% (harmful effect) nausea by 113% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 1.02 [0.75 1.38] | p=1.00 | 0 | 779 | 3 | Bezwoda,Buzdar b,Buzdar c, | | objective response (ORR) | 1.14 [0.74 1.76] | p=1.00 | 0 | 779 | 3 | Bezwoda,Buzdar b,Buzdar c, | | death (overall survival) | 1.35 [0.49 3.73] | p=1.00 | 0 | -18 | 1 | Bezwoda, | | hot flushes | 1.39 [0.89 2.18] | p=1.00 | 0 | 779 | 3 | Bezwoda,Buzdar b,Buzdar c, | | rash | 0.96 [0.56 1.66] | p=1.00 | 0 | 683 | 2 | Buzdar b,Buzdar c, | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | 0.89 [0.50 1.61] | p=1.00 | 0 | 683 | 2 | Buzdar b,Buzdar c, | | vomiting | 2.22 [1.28 3.84] | p=0.04 | 0 | 683 | 2 | Buzdar b,Buzdar c, | | diarrhoea | 1.02 [0.62 1.66] | p=1.00 | 0 | 683 | 2 | Buzdar b,Buzdar c, | | nausea | 2.13 [1.46 3.10] | p=0.04 | 0 | 779 | 3 | Bezwoda,Buzdar b,Buzdar c, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| fadrozole vs tamoxifen | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 1.06 [0.59 1.91] | p=1.00 | 0 | 221 | 1 | Thuerlimann, | | objective response (ORR) | 1.22 [0.73 2.05] | p=1.00 | 0 | 301 | 2 | Thuerlimann,Falkson, | | death (overall survival) | 0.91 [0.39 2.13] | p=1.00 | 0 | -18 | 1 | Thuerlimann, | | vaginal bleeding | no data | | arthralgia | no data | | hot flushes | 0.96 [0.57 1.63] | p=1.00 | 0 | 287 | 2 | Falkson,Thuerlimann, | | rash | 3.09 [0.12 76.65] | p=1.00 | 0 | 211 | 1 | Thuerlimann, | | thromboembolic AE | 0.11 [0.01 2.15] | p=1.00 | 0 | 211 | 1 | Thuerlimann, | | vomiting | no data | | diarrhoea | no data | | nausea | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
